Nkarta Inc. | Natural Killer Cell Therapy Autoimmune Care
Nkarta is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf natural killer (NK) cell therapies to treat autoimmune disease. Combining cell expansion and cryopreservation platforms with proprietary engineering technologies, Nkarta's lead candidate NKX019 uses donor-derived NK cells to target B cell-mediated autoimmune conditions including lupus, enabling outpatient community health setting dosing.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2024
Jul 2020
Sep 2019
Jan 2016
Jan 2015
Create a free account to see which investors have funded this company.
Create Free Account
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
